Transcriptome fingerprinting of aberrant fibroblast activation unlocks effective therapeutics to tackle cardiac fibrosis
Science Advances · 2025
DOI: 10.1126/sciadv.adx0968 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Advances, 2025. Verfasst von Mathieu Cinato und 12 weiteren Autor:innen. Beteiligte Einrichtung: National Institute of Health and Medical Research (INSERM) U1297-University of Toulouse, 31432 Toulouse Cedex 4, France. Hauptthemen laut MEDLINE: Fibroblasts, Transcriptome, Myocardium, Gene Expression Profiling. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Aberrant activation of fibroblasts is a pivotal component of cardiac fibrosis predisposing to heart failure. However, the molecular regulation of the functional state of cardiac fibroblasts in fibrosis resolution remains largely unexplored, and therefore, effective antifibrosis therapies are still lacking. By translating mouse transcriptomics to humans, we unlocked common molecular denominators connecting the fibroblast phenotypic state and fibrogenic signaling pathways in cardiac fibrosis. Through the construction of a fibroblast-specific transcriptional gene regulatory network, we found ITGAL and DUSP9 as key druggable targets for human myocardial fibrosis. A computational drug repurposing approach predicted 367 antifibrotic candidate compounds for heart disease. In primary cardiac fibroblasts derived from patients with heart failure, we provided experimental validation of the top 2–ranked repositioned drug candidates and their combination. These innovative approaches facilitate the identification of potential targets and drug candidates for cardiac fibrosis, providing actionable opportunities for clinical translation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- National Institute of Health and Medical Research (INSERM) U1297-University of Toulouse, 31432 Toulouse Cedex 4, France.
- Department of Molecular and Clinical Medicine/Wallenberg Laboratory, Institute of Medicine, Sahlgrenska Academy at University of Gothenburg and Sahlgrenska University Hospital, Gothenburg, Sweden.
- I. Horbachevsky Ternopil National Medical University, 46001 Ternopil, Ukraine.
- GeneXplain GmbH, Wolfenbuettel, Germany.
- Royal College of Surgeons in Ireland (RCSI), 123 St Stephen's Green, Dublin 2, D02 YN77, Ireland.
- School of Pharmacy, University of Camerino, 62032 Camerino, Italy.
ORCID-Profile: Mathieu Cinato, Ryeonshi Kang, Solomiia Kramar, Nathalie Pizzinat, Audrey Swiader, Alexander Kel, Aleksandr Kalmykov, Daria Stelmashenko, Ilenia Martinelli, Charlotte Laborde, Oksana Kunduzova
Zitieren
APA
Cinato, M., Kang, R., Kramar, S., Savchenko, L., Pizzinat, N., Swiader, A., Kel, A., Kalmykov, A., Stelmashenko, D., Martinelli, I., Roncalli, J., Laborde, C., & Kunduzova, O. (2025). Transcriptome fingerprinting of aberrant fibroblast activation unlocks effective therapeutics to tackle cardiac fibrosis. Science Advances. https://doi.org/10.1126/sciadv.adx0968
Vancouver
Cinato M, Kang R, Kramar S, Savchenko L, Pizzinat N, Swiader A, et al. Transcriptome fingerprinting of aberrant fibroblast activation unlocks effective therapeutics to tackle cardiac fibrosis. Science Advances. 2025. doi:10.1126/sciadv.adx0968
BibTeX
@article{Cinato2025,
author = {Cinato, Mathieu and Kang, Ryeonshi and Kramar, Solomiia and Savchenko, Lesia and Pizzinat, Nathalie and Swiader, Audrey and Kel, Alexander and Kalmykov, Aleksandr and Stelmashenko, Daria and Martinelli, Ilenia and Roncalli, Jerome and Laborde, Charlotte and Kunduzova, Oksana},
title = {Transcriptome fingerprinting of aberrant fibroblast activation unlocks effective therapeutics to tackle cardiac fibrosis},
journal = {Science Advances},
year = {2025},
doi = {10.1126/sciadv.adx0968}
}
EUVIMED